Functional Antibody Screening meets Antibody Engineering

The merger of two companies is in itself nothing unusual in the business world. But when two successful spin-offs – VELABS Therapeutics and ARAXA Biosciences – from Europe’s most renowned institute for life science research and instrumentation, the European Molecular Biology Laboratory (EMBL) merge into one corporate entity, it is not only special for us.

The new company is called VERAXA Biotech and combines the complementary strengths in droplet-based microfluidic screening technology of VELABS with antibody modulation and development of ARAXA.

By merging ARAXA’s unique and proprietary ADC technology with VELABS’ superior antibody screening engine expertise, VERAXA becomes a new center of excellence for all pharmaceutical and biotech partners seeking to benefit from more efficient antibody development. The superior complementary skills under one roof will be a key advantage for pharma partners, enabling them to develop more and better antibody lead candidates against complex and pharmacologically important signaling receptors such as GPCRs in a shorter time. Existing target product profiles will be further enhanced and sharpened by our proprietary and proven orthogonal click chemistry modification and conjugation technology.

We look forward to continued collaboration together and an exciting future in the development of new antibody-based drugs and therapies.

‍

Contact

Dr. Christoph Antz
Managing Director

Veraxa Biotech GmbH

Meyerhofstrasse 1
69117 Heidelberg
Germany

Carl-Friedrich-Gauß-Ring 5
69124 Heidelber
Germany

+49 6221 4263365
info@veraxa.com